Consensus Cytek Biosciences, Inc.

Equities

CTKB

US23285D1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
6.27 ^USD	-1.72%		-1.57%	-31.25%

May. 08	Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 Revenue $44.9M, vs. Street Est of $43.6M	MT
May. 08	Transcript : Cytek Biosciences, Inc., Q1 2024 Earnings Call, May 08, 2024

Evolution of the average Target Price on Cytek Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f1cfd275417b90fa.j_A7F7iwF_YbDAuaqCfIni31hjhrziEAVziUhpdZiXQ.4YEDW-DVSKJXdTPv0mOR31ex7ww_nBROMwnF9sAduCW-h0Nf3P1ask1EQg~0a1aa4f42a02324013fd1d1bf88e7f96

Analyst Recommendations on Cytek Biosciences, Inc.

Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing	Mar. 20	MT
Piper Sandler Trims Price Target on Cytek Biosciences to $10 From $11, Maintains Overweight Rating	Mar. 06	MT
Stephens Initiates Cytek Biosciences With Overweight Rating, Price Target is $9	Dec. 14	MT
Morgan Stanley Trims Price Target on Cytek Biosciences to $7 From $8, Maintains Equalweight Rating	Nov. 09	MT
Morgan Stanley Cuts Cytek Biosciences' Price Target to $8 From $13, Keeps Equalweight Rating	23-10-24	MT
Raymond James Initiates Cytek Biosciences With Market Perform Rating	23-07-19	MT
Morgan Stanley Adjusts Price Target on Cytek Biosciences to $13 From $14, Maintains Equal-Weight Rating	23-05-11	MT
Goldman Sachs Adjusts Cytek Biosciences' Price Target to $12 From $14, Keeps Buy Rating	23-05-10	MT
Piper Sandler Adjusts Price Target on Cytek Biosciences to $15 From $18, Maintains Overweight Rating	23-03-07	MT
Morgan Stanley Trims Cytek Biosciences' Price Target to $14 From $15, Maintains Equalweight Rating	23-03-02	MT
Goldman Sachs Adjusts Cytek Biosciences' Price Target to $14 From $16, Keeps Buy Rating	23-03-02	MT
Piper Sandler Adjusts Cytek Biosciences' Price Target to $16 from $12, Maintains Overweight Rating	22-08-18	MT
Morgan Stanley Adjusts Price Target on Cytek Biosciences to $15 From $11, Maintains Equalweight Rating	22-08-12	MT
Goldman Sachs Adjusts Cytek Biosciences' Price Target to $17 From $15, Keeps Buy Rating	22-08-11	MT
Goldman Sachs Raises Cytek Biosciences' Price Target to $15 From $12, Buy Rating Maintained	22-07-14	MT
Piper Sandler Adjusts Price Target on Cytek Biosciences to $12 From $17, Reiterates Overweight Rating	22-05-16	MT
Morgan Stanley Lowers Price Target for Cytek Biosciences to $11 From $18, Maintains Equalweight Rating	22-05-12	MT
Goldman Sachs Lowers Cytek Biosciences Price Target to $12 From $14, Buy Rating Maintained	22-05-12	MT
Goldman Sachs Adjusts Cytek Biosciences' Price Target to $14 from $28, Keeps Buy Rating	22-04-13	MT
Piper Sandler Adjusts Cytek Biosciences' Price Target to $17 From $20, Reiterates Overweight Rating	22-03-01	MT
Morgan Stanley Adjusts Cytek Biosciences Price Target to $18 From $27, Maintains Equalweight Rating	22-02-15	MT
CYTEK BIOSCIENCES : Cowen & Co Initiates Coverage on Cytek Biosciences With Outperform Rating	21-08-17	MT
CYTEK BIOSCIENCES : Morgan Stanley Starts Cytek Biosciences at Equal-Weight With $26 Price Target	21-08-17	MT
CYTEK BIOSCIENCES : Goldman Sachs Starts Cytek Biosciences at Buy With $28 Price Target	21-08-17	MT
CYTEK BIOSCIENCES : Piper Sandler Starts Cytek Biosciences at Overweight With $28 Price Target	21-08-17	MT